赢了业绩输了规模！绩优主动权益基金遭ETF“偷袭” 什么情况？

Group 1 - The core phenomenon observed in the market is that active equity funds have outperformed ETFs in terms of performance, but ETFs have significantly outpaced active funds in terms of scale growth [1][2][3] - The innovation drug sector has seen a remarkable surge, with a total of 17 funds doubling their performance this year, of which 10 are active equity funds and 7 are innovation drug-themed ETFs [2][3] - Despite the strong performance of active equity funds, their scale growth is lagging behind that of ETFs, indicating a preference among investors for ETFs to capture the benefits of policy and industry breakthroughs [3][4] Group 2 - The rapid growth of ETFs has led to a significant increase in their number, scale, and coverage, which has put pressure on active equity funds [6] - ETFs attract investors due to their transparent holdings, flexible trading features, and lower management fees compared to active equity funds, making them a more appealing option for many [6][7] - The market trend shows that while ETFs are gaining popularity, active equity funds still hold value in terms of identifying undervalued stocks and smoothing out volatility [6][7] Group 3 - The recent performance of ETFs, particularly in sectors like human robotics and brokerage, has outstripped that of active equity funds, highlighting a shift in investor preference towards passive investment strategies [4][6] - The influx of funds into ETFs has been particularly pronounced during high-growth periods, such as the recent boom in the innovation drug sector, which has provided a prime opportunity for ETF expansion [3][4] - The competitive landscape is evolving, with fund companies increasingly focusing on passive investment strategies, further constraining the space for active equity funds [6][7]